There are bigger -- much bigger -- pharmas competing in the radioactive seed biz. ISR has not done well over the years competing! That's the main problem besides the hyped-up press release ISR published yesterday. Adam did you a service by looking for the truth.
That's to be commended. You guys should know that there is robust competition in the seed s business of radioactive short lived isotopes. ISR is a small and weak player in this biz. That's a fact. The biggest mkt for these seeds is prostate cancer. It's too bad ISR has not been able to establish itself as a leader. ISR I try to distinguish itself as a better product due to its shorter lived radioactivity and safe chemical make-up. That's what I would try to do when competing with the likes of mega companies like Bard. Good luck guys, but Adam was spot on right for coming down hard on ISR's hype. Don't hard on attacking the messenger, Adam. He did a good job in hype-busting.
biotechman, in case someone takes to heart and believes what you say, the record needs to be aired about your hero Evan. Under his watch, ANX, now name changed to MSTX (and note he was booted out of ANX), spiked to $123.75 a share in 2006 and is now trading, post reverse splits, at .47. That's equivalent of Evan overseeing a fall form $247.50 a share all the way down to $1. If I remember correctly, you were an initial cheerleader of Evan who evolved into a bitter critic of him at the horrible end of his stewardship. How can you be pumping him as a responsible CEO after what happened with Adventrx? Good luck to you and Evan this time around, but please stick to the truth, even if it's disquieting. You wouldn't want to mislead prospective investors, would you?